165 related articles for article (PubMed ID: 8763466)
1. Employment of terbinafine against Pneumocystis carinii infection in rat models.
Contini C; Colombo D; Cultrera R; Prini E; Sechi T; Angelici E; Canipari R
Br J Dermatol; 1996 Jun; 134 Suppl 46():30-2; discussion 40. PubMed ID: 8763466
[TBL] [Abstract][Full Text] [Related]
2. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
[TBL] [Abstract][Full Text] [Related]
3. Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia.
Contini C; Angelici E; Canipari R
J Antimicrob Chemother; 1999 Feb; 43(2):301-4. PubMed ID: 11252340
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
5. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
Hughes WT
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
[TBL] [Abstract][Full Text] [Related]
6. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.
Walzer PD; Ashbaugh A
Antimicrob Agents Chemother; 2002 Feb; 46(2):514-6. PubMed ID: 11796365
[TBL] [Abstract][Full Text] [Related]
7. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.
Comley JC; Sterling AM
Antimicrob Agents Chemother; 1995 Apr; 39(4):806-11. PubMed ID: 7785975
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.
Hughes WT; Gray VL; Gutteridge WE; Latter VS; Pudney M
Antimicrob Agents Chemother; 1990 Feb; 34(2):225-8. PubMed ID: 2327770
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii.
Cirioni O; Giacometti A; Balducci M; Burzacchini F; Scalise G
J Antimicrob Chemother; 1995 Oct; 36(4):740-2. PubMed ID: 8591953
[No Abstract] [Full Text] [Related]
10. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
Korraa H; Saadeh C
South Med J; 1996 Mar; 89(3):272-7. PubMed ID: 8604455
[TBL] [Abstract][Full Text] [Related]
11. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
Hughes W; Leoung G; Kramer F; Bozzette SA; Safrin S; Frame P; Clumeck N; Masur H; Lancaster D; Chan C
N Engl J Med; 1993 May; 328(21):1521-7. PubMed ID: 8479489
[TBL] [Abstract][Full Text] [Related]
12. Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.
Hughes WT; Sillos EM; LaFon S; Rogers M; Woolley JL; Davis C; Studenberg S; Pattishall E; Freeze T; Snyder G; Staton S
J Infect Dis; 1998 Apr; 177(4):1046-56. PubMed ID: 9534981
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats.
Sun P; Tong Z
Med Mycol; 2014 Nov; 52(8):798-803. PubMed ID: 25288652
[TBL] [Abstract][Full Text] [Related]
14. Antipneumocystis activity of 17C91, a prodrug of atovaquone.
Comley JC; Yeates CL; Frend TJ
Antimicrob Agents Chemother; 1995 Oct; 39(10):2217-9. PubMed ID: 8619570
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study.
Meyers B; Borrego F; Papanicolaou G
Liver Transpl; 2001 Aug; 7(8):750-1. PubMed ID: 11510024
[TBL] [Abstract][Full Text] [Related]
16. The scid mouse as an experimental model for the evaluation of anti-Pneumocystis carinii therapy.
Kunz S; Junker U; Blaser J; Joos B; Meyer B; Zak O; O'Reilly T
J Antimicrob Chemother; 1995 Jul; 36(1):137-55. PubMed ID: 8537261
[TBL] [Abstract][Full Text] [Related]
17. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis.
Brun-Pascaud M; Chau F; Simonpoli AM; Girard PM; Derouin F; Pocidalo JJ
J Infect Dis; 1994 Sep; 170(3):653-8. PubMed ID: 8077724
[TBL] [Abstract][Full Text] [Related]
18. [New aspects of epidemiology and treatment of Pneumocystis carinii infection].
Powierska-Czarny J; Gospodarek E; Czerwionka-Szaflarska M
Pol Merkur Lekarski; 2004 Nov; 17(101):534-7. PubMed ID: 15754652
[TBL] [Abstract][Full Text] [Related]
19. Low-dose trimethoprim-sulfamethoxazole alone and in association with zidovudine for prevention and treatment of murine Pneumocystis carinii pneumonia.
Brun-Pascaud M; Girard PM; Pocidalo JJ
Antimicrob Agents Chemother; 1992 Oct; 36(10):2328-30. PubMed ID: 1444313
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
Aviles P; Aliouat EM; Martinez A; Dei-Cas E; Herreros E; Dujardin L; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 May; 44(5):1284-90. PubMed ID: 10770763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
